Companies › Vaxine
2 active drug programs in 3 registered trials: 3 Phase 1; Oncology, Infectious disease; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Tozinameran (CpG55) Spike glycoprotein vaccine antigen | – | Phase 1 | covid19 Infection | Dec 2026 |
| Radvax Autologous tumor vaccine with polysaccharide adjuvant | – | Phase 1 | Solid Tumor | Feb 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06355232 | Tozinameran (CpG55) | Phase 1 | covid19 Infection | Infectious disease | Dec 2026 |
| NCT06355232 | Tozinameran (CpG55) | Phase 1 | covid19 Infection | Infectious disease | Dec 2026 |
| NCT05807035 | Radvax | Phase 1 | Solid Tumor | Oncology | Feb 2028 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.